SNIBE(SZ:300832)2024-10-31 10:35Financial Performance - The company achieved operating revenue of 3.414 billion yuan, representing a year-on-year growth of 17.41% [1] - Net profit attributable to shareholders reached 1.384 billion yuan, an increase of 16.59% compared to the same period last year [1] - In the domestic market, the company recorded a main business income of 2.196 billion yuan, with a growth rate of 14% [1] - Revenue from domestic reagent sales grew nearly 13% year-on-year [1] Market Challenges - The decline in revenue growth in the third quarter was attributed to external pressures, including delays in hospital procurement due to industry regulations and the impact of centralized procurement [3] - The sales of reagents faced short-term adjustments due to reduced testing volumes in certain projects [3] Product and Market Expansion - The company installed 1,248 fully automated chemiluminescence analyzers in the domestic market, with large machines accounting for 75% of installations [3] - The company launched 29 new SATLARS T8 production lines, enhancing sales of routine reagents through expansion into large medical terminal clients [3] - In the overseas market, the company achieved main business income of 1.212 billion yuan, a year-on-year increase of 25% [3] - Overseas reagent business revenue grew by 32% year-on-year, with a 37% increase in the third quarter [3] Strategic Focus - The company is focusing on expanding its influence in high-level hospitals and promoting its high-speed machines, X8 and X6, in large terminal applications [3] - The expected upgrade of overseas customers is anticipated to lay a solid foundation for long-term operational growth [3]